# TriLink BioTechnologies

Maravai LifeSciences subsidiary — world-leading mRNA CDMO supplying CleanCap capping analogs and GMP-grade mRNA to Moderna, BioNTech, and 500+ biotech clients.

Source: https://en.bioecon.ru/companies/trilink/
Updated: 2026-06-19

- Country: United States
- Revenue: ~$100M
- Employees: ~500 emp

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Founded | 1996 | https://www.trilinkbiotech.com/about-us/ |
| Production site | San Diego, California (multiple campus locations) and Jupiter, Florida | https://investors.maravai.com/news-events/press-releases/detail/128/trilink-opens-gmp-enzyme-manufacturing-facility-enabling-integrated-ivt-supply-from-rd-to-commercial-scale, https://sdbj.com/real-estate/commercial/trilink-biotechnologies-expands-campus/, https://www.trilinkbiotech.com/press-releases/trilink-biotechnologies-announces-new-san-diego-facility-for-late-phase-mrna-drug-substance-production |
| Capacity | mRNA manufacturing capacity from 1g to >100g per batch; 118,000 sq ft manufacturing facility in San Diego; 5,000 sq ft GMP enzyme facility in Jupiter, Florida | https://investors.maravai.com/news-events/press-releases/detail/44/maravai-lifesciences-offers-end-to-end-mrna-production-with-the-launch-of-trilink-biotechnologies-plasmid-dna-manufacturing-services, https://www.trilinkbiotech.com/, https://www.trilinkbiotech.com/press-releases/trilink-biotechnologies-announces-new-san-diego-facility-for-late-phase-mrna-drug-substance-production |
| Certification | ISO 9001:2015 and ICH Q7 compliant quality system | https://www.trilinkbiotech.com/, https://www.trilinkbiotech.com/about-us/ |
| Revenue | $119.8 million (for the year ended December 31, 2025) | https://investors.maravai.com/news-events/press-releases/detail/123/maravai-lifesciences-reports-fourth-quarter-and-full-year-2025-financial-results, https://investors.maravai.com/sec-filings/all-sec-filings/content/0001823239-26-000011/0001823239-26-000011.pdf, https://www.sec.gov/Archives/edgar/data/1823239/000182323926000005/exhibit991-q42025.htm |

Independent sources: investors.maravai.com, sdbj.com, sec.gov

## Technologies

- [mRNA platforms & LNP delivery](https://en.bioecon.ru/technology/mrna-platforms-lnp-delivery/)
- [Prime editing](https://en.bioecon.ru/technology/prime-editing/)